Why The Street Keeps Doubting Gilead
Gilead Sciences (NASDAQ: GILD ) reported another eye-popping quarter last week, with total revenue shooting up by 52% year over year:
Not surprisingly, most of this growth came from the company's hepatitis C franchise of Harvoni and Sovaldi, which generated $4.55 billion in sales during the three-month period.
Despite several consecutive quarters of crushing the Street's estimates, though, Gilead's share price has under-performed the high-flying biotech industry as a whole:
Hey, check out all the research scientist jobs. Post your resume today!
Not surprisingly, most of this growth came from the company's hepatitis C franchise of Harvoni and Sovaldi, which generated $4.55 billion in sales during the three-month period.
Despite several consecutive quarters of crushing the Street's estimates, though, Gilead's share price has under-performed the high-flying biotech industry as a whole:
Hey, check out all the research scientist jobs. Post your resume today!